The Food and Drug Administration held a public hearing on September 14 on how psychedelic drugs might someday be used as supervised treatments, and the public has until October 5 to weigh in. Electronic comments must be submitted to the agency's Federal Register docket by 11:59 p.m. Eastern Time that day.
At the session, held in person at the FDA's White Oak campus in Silver Spring, Maryland, and online, doctors, veterans, pharmacists, and therapists urged regulators to set clear safety and access standards for psychedelic-assisted therapy, Reuters reported. Experts said any approved treatment must include trained staff in the room during sessions, along with proper screening, follow-up care, and community support.
